Nkarta Inc - ESG Rating & Company Profile powered by AI
This webpage contains a zero-cost ESG report covering Nkarta Inc. The report of Nkarta Inc was assembled by All Street Sevva using advanced artificial intelligence. The SDG assessment for Nkarta Inc indicates its transparency towards the United Nations Sustainable Development Goals.
Nkarta Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 4.0, social score of 1.6 and governance score of 3.2.
2.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
| 1336 | Sensorion SA | 3.0 | Medium |
| 1353 | Nkarta Inc | 2.9 | Medium |
| 1353 | Caribou Biosciences Inc | 2.9 | Medium |
| 1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Nkarta Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Nkarta Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Nkarta Inc report the average age of the workforce?
Sign up for free to unlockDoes Nkarta Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Nkarta Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Nkarta Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Nkarta Inc offer flexible work?
Sign up for free to unlockDoes Nkarta Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Nkarta Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Nkarta Inc conduct supply chain audits?
Sign up for free to unlockDoes Nkarta Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Nkarta Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Nkarta Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Nkarta Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Nkarta Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Nkarta Inc disclose water use targets?
Sign up for free to unlockDoes Nkarta Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Nkarta Inc have a product recall in the last two years?
Sign up for free to unlockDoes Nkarta Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Nkarta Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Nkarta Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Nkarta Inc disclose parental leave metrics?
Sign up for free to unlockDoes Nkarta Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Nkarta Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Nkarta Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Nkarta Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Nkarta Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Nkarta Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Nkarta Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Nkarta Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Nkarta Inc disclose its waste policy?
Sign up for free to unlockDoes Nkarta Inc report according to TCFD requirements?
Sign up for free to unlockDoes Nkarta Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Nkarta Inc disclose energy use targets?
Sign up for free to unlockDoes Nkarta Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Nkarta Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Nkarta Inc
These potential risks are based on the size, segment and geographies of the company.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.